Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.

Fiche publication

Date publication

octobre 2022

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland

Tous les auteurs :
Justeau G, Huchot E, Simonneau Y, Roa M, Le Treut J, Le Garff G, Bylicki O, Schott R, Bravard AS, Tiercin M, Lamy R, De Chabot G, Marty A, Moreau D, Locher C, Bernier C, Chouaid C, Descourt R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36323057

Résumé

Few data are available on the impact of KRAS mutation in patients with advanced non-squamous non-small cell lung cancer (aNSCLC) treated with immunotherapy. This analysis assessed the impact of KRAS mutation on the efficiency of first-line pembrolizumab immunotherapy in aNSCLC patients with PD-L1 ≥ 50 %.